Keyphrases
Anticoagulation
100%
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO)
100%
Argatroban
100%
Heparin
42%
Patient Demographics
28%
Potential Alternatives
28%
Therapeutic Target
28%
Activated Clotting Time
28%
Unfractionated Heparin
28%
Well-defined
14%
Safety Efficacy
14%
Infusion Rate
14%
Web-based
14%
Complication Rate
14%
Adult Patients
14%
MEDLINE
14%
Embase
14%
PubMed
14%
Continuous Infusion
14%
Bleeding Complications
14%
Dosing Strategy
14%
Systematic Literature Review
14%
Heparin-induced Thrombocytopenia
14%
Starting Dose
14%
Loading Dose
14%
Thromboembolic Complications
14%
Anticoagulant Agents
14%
Extracorporeal Membrane Oxygenation Support
14%
Alternative Anticoagulants
14%
Direct Thrombin Inhibitors
14%
Monitoring Approach
14%
Qualitative Synthesis
14%
Antithrombin Deficiency
14%
Main Agents
14%
Anticoagulation Strategy
14%
Medicine and Dentistry
Anticoagulation
100%
Systematic Review
100%
Extracorporeal Membrane Oxygenation
100%
Argatroban
100%
Heparin
71%
Patient Population
28%
Activated Clotting Time
28%
Bleeding
14%
Infusion Rate
14%
Cohort Analysis
14%
Thromboembolism
14%
Prospective Study
14%
Continuous Infusion
14%
Antithrombotic
14%
Heparin-Induced Thrombocytopenia
14%
Loading Drug Dose
14%
Direct Thrombin Inhibitor
14%
Antithrombin III Deficiency
14%
Pharmacology, Toxicology and Pharmaceutical Science
Argatroban
100%
Heparin
71%
Clotting Time
28%
Bleeding
14%
Anticoagulant Agent
14%
Thromboembolism
14%
Prospective Study
14%
Cohort Study
14%
Heparin Induced Thrombocytopenia
14%
Thrombin Inhibitor
14%
Antithrombin Deficiency
14%